-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $290

Benzinga·08/03/2026 21:18:17
Listen to the news
Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $282 to $290.